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Summary
BACKGROUND: Previous cross-sectional studies report-
ed a high prevalence of ascending aorta dilations/
aneurysms in male adults with Fabry disease, indepen-
dently of cardiovascular risk factors.
AIMS OF THE STUDY: To characterise the remodelling of
the ascending aorta in classic Fabry disease under long-
term enzyme replacement therapy.
METHODS: Diameter of the ascending aorta was mea-
sured with magnetic resonance imaging at the sino-tubular
junction (STJ), and proximal (pAsAo), and distal ascend-
ing aorta (dAsAo) at baseline, and after 5 and 10 years
of enzyme replacement therapy in 15 adult Fabry patients
(10 males; 5 females).
RESULTS: Over a mean follow-up of 9.5 years, the annual
expansion rates measured in 10 males with Fabry disease
were 0.41 ± 0.16, 0.36 ± 0.25 and 0.41 ± 0.26 mm/y at
the STJ, pAsAo and dAsAo, respectively. Expansion rate
at the pAsAo level in male patients was significantly high-
er than the expected expansion projected from theoretical
normal values: 0.36 ± 0.25 vs 0.13 ± 0.05, p = 0.017. In
5 females, the annual expansion rates at the STJ, pAsAo
and dAsAo were 0.14 ± 0.11, 0.21 ± 0.18 and 0.26 ±
0.24 mm/y, respectively. There was no significant differ-
ence from the projected normal expansion rate at the level
of the pAsAo: 0.21 ± 0.18 vs 0.13 ± 0.04, p = 0.39.
CONCLUSION: Our data suggest that the remodelling of
the ascending aorta is more pronounced in male patients
with Fabry disease under long-term enzyme replacement
therapy compared with the progression observed in a
large population study.
Key words: aorta, atherosclerosis, Fabry disease, remod-
elling, enzyme replacement therapy, dilation
Introduction
Fabry disease is a rare X-linked disorder caused by de-
ficiency of the lysosomal enzyme alpha-galactosidase A
(α-Gal A). This defect leads to progressive accumulation
of glycosphingolipids (GSL) in many tissues and organs,
and in particular in endothelial and vascular smooth mus-
cle cells (VSMC) of the arterial tree [1]. Males affected by
the classic form of the disease, defined as a residual α-Gal
A activity <1%, develop vascular abnormalities. Early vas-
cular manifestations, appearing from childhood and ado-
lescence, include angiokeratomas, conjunctival and retinal
vessel tortuosity and dilation, hearing loss and priapism
[2]. In adulthood, the majority of males suffer from chronic
renal insufficiency, as well as cardiovascular and cere-
brovascular complications responsible for premature death
[3]. The clinical presentation of heterozygous females is
more variable and ranges from a silent course to severe dis-
ease with multiorgan involvement similar to males [4].
The main vascular structural change observed in nor-
motensive adults with Fabry disease is a marked and accel-
erated increase in the intima-media thickness (IMT) of the
arterial wall, via a process distinct from atherosclerosis [5].
Arterial remodelling is further characterised by progressive
vascular dilation and elongation of the conduits, resulting
in a tortuous appearance, particularly in the basilar trunk
and conjunctival and retinal vessels [6]. A high prevalence
of asymptomatic dilation and aneurysms of the proximal
ascending aorta (pAsAo), which occurred at a younger age
compared with the general population, was also previous-
ly reported in male patients with the classic form of Fabry
disease [7]. Female patients may also develop dilation of
the pAsAo, but at a significantly lower rate compared to
male patients and generally at an older age [7].
Since 2001, enzyme replacement therapy (ERT) has be-
come commercially available and is recommended for pa-
tients with Fabry disease presenting early clinical signs of
kidney, heart or brain involvement [8]. Whereas several
studies have characterised the effect of long-term ERT on
cardiac, renal and cerebral outcomes, no data are current-
ly available regarding the evolution of the aortic remodel-
ling process under long-term ERT [9, 10]. The aim of the
present study was to compare the remodelling of the as-
cending aorta in adult patients with Fabry disease under
long-term ERT with the normal aortic remodelling com-
puted from large population data.
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Materials and methods
Study population
Fifteen adult patients with classic Fabry disease, included
in our prospective cohort (Service of Genetic Medicine of
the Lausanne University Hospital) from 1 October 2000
to 31 December 2015, and for whom a minimal follow-
up of 5 years under ERT was available, were enrolled in
the study. In male patients, classic Fabry disease was con-
firmed on the basis of a residual α-Gal A activity in leuco-
cytes <1%. In females, the diagnosis of classic Fabry dis-
ease was confirmed by means of genetic analysis. These
patients presented initially with multisystem involvement
of the disease and received ERT (agalsidase alfa, Repla-
gal®, Shire Pharmaceutical Inc, 0.2 mg/kg body weight in-
travenously every other week) after confirmation of the di-
agnosis.
Exclusion criteria were: presence of a bicuspid aortic
valve, valvular aortic stenosis or insufficiency considered
at least mild, signs of heart failure (ejection fraction of
the left ventricle <50%) at baseline, and pregnancy during
follow-up. Written informed consent was obtained from
all patients. The Institutional Review Boards approved the
study.
All patients underwent a baseline assessment at T0, before
the initiation of ERT, which included physical examina-
tion, blood pressure measurement, laboratory blood tests,
transthoracic echocardiography and cardiac magnetic reso-
nance imaging (CMR) of the thoracic aorta. The same as-
sessment was repeated after 5 (T5) and 10 years (T10) of
ERT.
Image acquisition
During the study, image acquisition at three time points
(T0, T5 and T10) was performed with CMR (Philips In-
tera, Philips Medical Systems, Amsterdam, the Nether-
lands, and Magnetom Symphony and Aera, Siemens, Er-
langen, Germany) using a phased-array receiver coil. At
the beginning of the study (from 2000 to 2006), the images
obtained in order to measure the diameters of the ascend-
ing aorta were acquired in the coronal, transverse and
oblique sagittal planes using single-phase ECG-gated
(end-diastolic phase) breath-hold images with a steady-
state free precession (SSFP) sequence (6 mm slice thick-
ness). From 2007 to the end of the study, a contrast-en-
hanced 3-D MR-angiography was additionally performed
during breath-holds in all patients, with injection of either
0.2 mmol/kg Gadolinium DOTA (Dotarem, Guerbet,
France) or Gadobutrol (Gadovist, Bayer, Switzerland).
CMR image analysis
Two experienced radiologists (S.D.H. and S.D.Q.)
analysed the anonymised images on a commercially avail-
able DICOM workstation (Advantage Window, GE
Healthcare, Milwaukee, USA), blinded to patient’s char-
acteristics and date of the examination. For each patient,
the maximal endoluminal diameters of the ascending aorta
at the sino-tubular junction (STJ), the proximal ascending
aorta at the level of the right pulmonary artery (pAsAo),
and of the distal ascending aorta (dAsAo) before the origin
of the brachiocephalic artery were measured (fig. 1). At
each level, the average diameter obtained from two mea-
surements in two orthogonal planes was used for analysis.
The annual aortic expansion rate, at each of the three afore-
mentioned levels of the ascending aorta, was calculated as
the difference in aortic diameter between baseline and the
last available follow-up divided by the time (in years) be-
tween baseline and the last available follow-up.
Figure 1: Measurement of the aortic diameters. A. With datasets where 3-D MR-angiography was not available, the luminal diameters, at end-
diastole, were directly measured on a non-cine SSFP acquisition of the ascending aorta in the coronal plane at three different levels: (1) sino-
tubular junction, (2) proximal ascending and (3) distal ascending aorta. B. In all cases where MR-angiography was available the maximal di-
ameters were measured on the individual aortic cross-section planes reconstructed at the level of the distal ascending aorta (C), proximal
ascending aorta (D) and sino-tubular junction (E)
Original article Swiss Med Wkly. 2017;147:w14517
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 2 of 7
Statistical analysis
Results are presented as mean ± standard deviation (SD)
for continuous variables and percentages for categorical
variables. Paired t-tests were used for longitudinal compar-
isons between aortic diameters at T0, T5 and T10. Cate-
gorical variables were compared with Fisher’s exact test.
For each patient, a predicted normal pAsAo was calculated
for each time-point by use of the regression formula report-
ed in the Multi-Ethnic Study of Atherosclerosis (MESA,
n = 3573 participants recruited in the general population):
predicted pAsAo diameter = [14.99 + (0.12 × age) + 1.79
(if male) + (4.63 × body surface area)] [11]. A predicted
annual aortic expansion rate was then calculated as the dif-
ference in predicted pAsAo diameter between baseline and
the last available follow-up divided by the time (in years)
between baseline and the last available follow-up. The
measured vs predicted pAsAo annual expansion rates were
compared with unpaired t-tests with unequal variance. All
the statistical analyses were performed using STATA 14
(StataCorp LP, Texas, USA). A value of p <0.05 was con-
sidered statistically significant.
Results
Study cohort
Fabry patients’ clinical characteristics at baseline are sum-
marized in table 1. Patients came from eight unrelated
families, whose mutations were: c.337T>C (F113L);
c.136C>T (H46Y); c.488G>T (G163V); c.658C>T
(R220X); c.901C>T (R301X); c.1284-1287 del
(L428Ffs*23); c.1046G>A (W349X); c.389insT (K130R).
In four male patients, residual α-Gal A activity in leuco-
cytes was undetectable; it was between 0.01 and 0.04 mE/
mg protein (range: 0.41–0.76) in the others (including the
patient with the F113L mutation). Alpha-Gal A activity
was not measured in the females. During the follow-up, 15/
15 patients had imaging at T5 (5.0 ± 1.5 years) and 12/15
at T10 (10.3 ± 1.6 years). Three male patients did not un-
dergo the T10 examination: one patient died of cardiac ar-
rest before T10, one had claustrophobia, and the last one
severe renal failure with glomerular filtration rate <30 ml/
min. The mean follow-up duration for the whole study was
therefore 9.5 ± 2.3 years.
At baseline, the male patients’ mean age was 36.6 ± 14.3
years (range: 15–60 years). Systolic and diastolic blood
pressure remained within normal range throughout the
study (5/10 patients received antihypertensive/antiprotein-
uric treatment), as did mean blood cholesterol (4/10 pa-
tients under statin treatment). Mean serum creatinine and
urinary protein levels were increased because of chronic
renal failure secondary to Fabry nephropathy in 6/10 pa-
tients. Two patients who reached end-stage renal disease
received a kidney transplant during their follow-up and one
patient started chronic haemodialysis.
At baseline, the female patients’ mean age was 41.6 ±
15.3 years (range: 22–59). Blood pressure was well con-
trolled (2/5 patients received antihypertensive/antiprotein-
uric medication). Mean blood cholesterol was within the
normal range (2/5 patients with statin therapy). One female
patient developed nephrotic syndrome due to Fabry
nephropathy. She received a kidney transplant from a liv-
ing donor after reaching end-stage renal disease.
Ascending aortic diameters at baseline in Fabry pa-
tients
In males, mean aortic diameters at the STJ, pAsAo and
dAsAo were 29.9 ± 5.9, 30.3 ± 6.6 and 29.0 ± 6.5 mm, re-
spectively. Although 5/10 patients fulfilled the criteria for
pAsAo dilation (diameter >19.5 mm/m2), the mean actual
diameter at the pAsAo was not statistically different from
the predicted diameter: 30.3 ± 6.6 vs 29.6 ± 1.7 mm, p =
0.77. Baseline aortic diameter at pAsAo depended strong-
ly on patient’s age, since a dilation was observed in all pa-
tients older than 40 years but in only one patient under 40
years of age (p = 0.048).
In female patients, the mean diameters at the STJ, pAsAo
and dAsAo were 27.4 ± 1.6, 29.7 ± 2.7 and 27.5 ± 1.1 mm,
respectively. A single 55-year-old female patient fulfilled
the criteria for pAsAo dilation. On average, the measured
diameter at the pAsAo was comparable to the predicted di-
ameter: 29.7 ± 2.7 vs 28.0 ± 1.8 mm, p = 0.28.
Expansion of the aortic diameters between T0 and T10
in Fabry patients
Mean pAsAo diameter was 30.3 ± 6.6 mm (16.6 ± 3.5 mm/
m2 body surface area) in male patients at T0. Mean in-
crease in pAsAo diameter was 1.83 ± 1.66 mm (95% con-
fidence interval [CI] 0.64–3.02, p = 0.007) between T0 and
T5, 1.91 ± 1.41 mm (95% CI 0.61–3.21, p = 0.01) between
T5 and T10 and 3.46 ± 1.39 mm (95% CI 2.17–4.75, p =
0.0006) between T0 and T10 (fig. 2). Mean annual expan-
sion rate of the pAsAo was significantly higher than the
predicted value calculated based on the MESA formula:
0.36 ± 0.25 mm/y vs 0.13 ± 0.05 mm/y, corresponding to a
difference of 0.23 mm/y (95% CI 0.05–0.41, p = 0.017) be-
tween actual and predicted annual expansion rate. A com-
Table 1: Clinical characteristics of the male and female Fabry popula-
tion at baseline.
Parameter Units Males
(n = 10)
Females
(n = 5)
Age years 36.5 ± 14.1 41.5 ± 15.1
Height cm 172.2 ± 4.9 168.2 ± 3.0
Weight kg 70.0 ± 10.1 64.6 ± 11.6
Body mass index kg/m2 23.6 ± 3.3 22.9 ± 4.9
Systolic blood
pressure
mm
Hg
122.3 ± 12.0 131.8 ± 16.6
Diastolic blood
pressure
mm
Hg
71.9 ± 10.3 78.0 ± 14.9
Serum total cho-
lesterol
mmol/
l
4.7 ± 1.1 5.5 ± 0.7
Serum HDL cho-
lesterol
mmol/
l
1.5 ± 0.3 1.7 ± 0.7
Serum LDL cho-
lesterol
mmol/
l
2.7 ± 0.8 3.5 ± 0.8
Serum triglyc-
erides
mmol/
l
1.1 ± 0.4 0.9 ± 0.2
Serum creatinine µmol/l 94.8 ± 33.0 71.2 ± 7.8
Proteinuria g/l 1.62 ± 2.50 1.14 ± 2.44
CRP mg/l 1.8 ± 2.5 2.6 ± 1.8
Current smokers n (%) 2 (20%) 0 (0%)
Antihypertensive
treatment
n (%) 7 (70%) 2 (40%)
Statin therapy n (%) 4 (40%) 2 (40%)
Diabetes n (%) 0 (0%) 0 (0%)
CRP = C-reactive protein; HDL = high-density lipoprotein; LDL = low-
density lipoprotein Creatinine: normal value: male <106 µmol/l; female
< 84 µmol/l
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parable significant increase in diameters was also observed
at the level of the STJ and dAsAo (table 2).
Mean pAsAo diameter was 29.7 ± 2.7 mm (17.2 ± 1.9 mm/
m2 body surface area) in female patients at T0. We ob-
served a significant increase in pAsAo diameter between
T0 and T10: mean increase 2.0 ± 1.6 mm (95% CI
0.03–3.93, p = 0.048). Likewise, the diameter progressed
significantly between T0 and T10 at the level of the STJ
and dAsAo (table 2). At the level of the pAsAo, the mean
annual expansion rate was 0.21 ± 0.18 mm/y. This value
was not significantly different from the expected expan-
sion of 0.13 ± 0.04 mm/y. The difference between actual
and predicted annual expansion rate was 0.08 mm/y (95%
CI 0.14–0.30, p = 0.39).
Comparison between ascending aortic expansion in
Fabry patients and normal population
At T0, 5/10 male patients were diagnosed with an abnor-
mally dilated pAsAo (fig. 3). These patients were signifi-
cantly older: 47.6 ± 8.6 vs 25.5 ± 8.2 years, p = 0.003, com-
pared with Fabry patients with a normal aortic diameter,
and also showed a trend toward higher mean serum creati-
nine concentration (112.8 ± 39.3 vs 76.8 ± 10.1 µmol/l; p
= 0.08) and higher diastolic blood pressure (77.6 ± 11.4 vs
66.2 ± 5.0 mm Hg; p = 0.08). Between T0 and T10, there
was no significant difference in mean aortic expansion rate
at pAsAo between patients with normal and dilated aorta
at baseline: 0.27 ± 0.06 vs 0.44 ± 0.15 mm/year, p = 0.35.
Discussion
This long-term longitudinal cohort study provides several
important findings regarding aortic remodelling in patients
with the classic form of Fabry disease: (1) the prevalence
of dilation of the pAsAo is high among untreated patients,
occurring in 50% of males and 20% of females, almost ex-
clusively after 40 years of age; (2)in male patients under
long-term ERT, the average annual expansion rate of the
AsAo is still more than twice as high as the normal annual
expansion rate projected from the transversal data of the
MESA study [11] (0.36 ± 0.25 mm/y vs 0.13 ± 0.05 mm/y,
p<0.017); (3) in male patients, remodelling of the ascend-
ing aorta is homogenous, with comparable baseline diam-
eters and annual aortic expansion rates at the STJ (0.41 ±
0.16 mm/y), pAsAo (0.36 ± 0.25 mm/y) and dAsAo (0.41
± 0.26 mm/y); and (4) accelerated aortic remodelling is not
found in treated heterozygous females (average annual ex-
pansion rate at the pAsAo: 0.21 ± 0.18 mm/y vs 0.13 ±
0.04 mm/y, p = 0.43).
Ageing in healthy males is associated with a progressive
increase in the ascending aortic diameter at the level of
the pAsAo, with a normal expansion rate between 0.9 [12]
and 1.2 mm [11] per decade, according to previous popu-
Figure 2: Progression of aortic diameters at the sino-tubular junction, proximal and distal ascending aorta between T0 and T5 and between T0
and T10 in males and females with Fabry disease. The two horizontal lines in the central panel indicate the expected progression in the gener-
al population according to MESA at 5 years (blue line) and at 10 years (red line). For each diameter progression, the box indicates the 25th
and the 75th percentile and the large diamond indicates the mean value. Outliers are depicted as small diamonds.
Table 2: Increase in measured aortic diameters in mm.
T0 to T5 p-value T5 to T10 p-value T0 to T10 p-value
Male patients n = 10 n = 7 n = 7
Sino-tubular junction 2.06 ± 1.20 0.0004 2.53 ± 1.21 0.002 4.54 ± 1.81 0.0006
Ascending aorta 1.83 ± 1.66 0.007 1.91 ± 1.41 0.01 3.46 ± 1.39 0.0006
Distal ascending aorta 1.91 ± 1.73 0.007 2.37 ± 1.23 0.002 3.96 ± 1.05 0.0001
Female patients n = 5 n = 5 n = 5
Sino-tubular junction 0.70 ± 0.76 0.11 0.80 ± 0.57 0.03 1.50 ± 1.59 0.03
Ascending aorta 0.72 ± 1.29 0.28 1.26 ± 1.65 0.16 1.98 ± 1.57 0.048
Distal ascending aorta 1.36 ± 1.19 0.06 1.34 ± 1.85 0.18 2.7 ± 2.07 0.04
All data are presented as mean ± SD
Figure 1: Measurement of the aortic diameters. A. With datasets where 3-D MR-angiography was not available, the luminal diameters, at end-diastole, were directly measured on
a non-cine SSFP acquisition of the ascending aorta in the coronal plane at three different levels: (1) sino-tubular junction, (2) proximal ascending and (3) distal ascending aorta.
B. In all cases where MR-angiography was available the maximal diameters were measured on the individual aortic cross-section planes reconstructed at the level of the distal
ascending aorta (C), proximal ascending aorta (D) and sino-tubular junction (E)
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lation studies. In our study, the longitudinal follow-up of
male patients with classic Fabry disease treated with ERT
showed an average expansion rate 2 to 3 times higher than
that observed in general population. In the absence of a
control group (untreated patients with classic Fabry dis-
ease), the efficacy of ERT in reducing the aortic expansion
rate cannot be directly assessed. Additionally, such accel-
erated aortic remodelling was not found in heterozygous
females. It is well known that heterozygous females have
a greater phenotypic variation than males [13]. However,
mean age of our female cohort was relatively low (41.5 ±
15.1 years) and a longer follow-up, beyond 60 years of age,
is probably warranted to detect pathological dilation of the
AsAo in females. To support this assumption, the only fe-
male patient with significant aortic dilation was among the
oldest in our cohort.
ERT currently represents the standard treatment for classic
Fabry disease and is most effective when started early in
the course of the disease, prior to the development of sig-
nificant kidney, heart and/or brain lesions [14, 15]. Indeed,
several studies reported a limited efficacy of long-term
ERT in both male and female patients with advanced dis-
ease at the time of the initiation of ERT [16, 17], espe-
cially if fibrosis had already developed in heart, kidney or
in the central nervous system [18]. Conversely, early ERT
initiation in younger male patients without significant kid-
ney involvement is associated with favourable outcome at
10-year follow-up with most patients remaining alive [10].
Moreover, the absence of cardiac involvement at the time
of ERT initiation, defined as an absence of left ventricular
hypertrophy (due to hypertrophy/hyperplasia of cardiomy-
ocytes) [9] or a normal ECG trace [19], is also associat-
ed in both male and female patients with an absence of
increased left ventricular mass at long-term follow-up. In
contrast, regarding the ascending aorta, we found that ini-
tiation of ERT before any dilation did not appear to pro-
vide any clear benefit in terms of expansion rate reduction
in male patients. Indeed, in our cohort, the average annu-
al aortic expansion rate under ERT in younger males (with
non-dilated pAsAo at baseline, age: 25.5 ± 8.2 years) was
not different from that of older patients (47.6 ± 8.6 years)
with significant aortic dilatation before ERT: 0.27 ± 0.06
vs 0.44 ± 0.15 mm/y, p = 0.35. However, it is possible
that the small size of the subgroups may limit the statistical
power of this comparison.
In the most recent Fabry Outcome Survey analysis, the es-
timated median survival in males on long-term treatment
is 77.5 years compared with 60 years in untreated males,
suggesting an important benefit of ERT on life expectancy
[20]. Hence, because of prolongation of life expectancy
with only a partial or limited impact on aortic remodelling,
patients on long-term ERT might have a greater lifetime
risk of developing a dilation/aneurysm of the AsAo. Al-
though, to date, no increased risk of AsAo dissection or
rupture has been reported in Fabry disease, we believe that
a periodic assessment of the ascending aorta is warranted
to exclude the development of large and potentially harm-
ful aneurysms principally in patients over 60 years of age.
Despite the fact that the cascade of events of Fabry disease-
related vasculopathy has been recently characterised, the
main underlying mechanism leading to accelerated aortic
expansion remains unclear [6]. Pompen et al. have reported
Figure 3: Individual profiles of aortic diameter increase in male and female patients with Fabry disease.
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the case of a 41-year-old man in whom the wall of the
aorta was thickened [21]. The main anomalies observed
were the presence of hypertrophied VSMC and the accu-
mulation of a protein-like substance among muscle fibres.
They also reported normal appearing elastic fibres with-
out any sign of parietal inflammation. In addition, Elleder
observed predominant storage of globotriaosylceramide in
VSMC in the media of arterial walls [22]. Cells distended
with storage material were necrotic. Shrunken and densi-
fied dead cells were also observed, with the formation of
hyaline, strongly PAS-positive structures, suggesting apop-
tosis. These structural anomalies may weaken the arteri-
al wall and promote the development of aortic dilation. In
contrast, in the main forms of familial thoracic aneurysm
and dissection, the primary underlying mechanism leading
to aneurysm is the breakdown of extracellular matrix pro-
teins and the accumulation of mucoid material and loss of
VSMC, in a process called cystic medial necrosis [23]. In
these forms, the micro-architectural changes lead to ves-
sel dilation, subsequent aneurysm formation and possible
dissection/rupture with diameters typically smaller than 50
mm.
Interestingly, a protective role of increased intima-media
thickness of the aorta has been reported. Among patients
presenting a dilation of the AsAo of more than 45 mm, aor-
tic dissection occurred at a significantly higher aortic di-
ameter to wall thickness ratio and a thinner aortic media
[24]. Hence, in classic Fabry disease, the abnormal in-
creased intima-media thickness of the aorta could limit the
risk of dissection.
Based on our observations, our local practice is to measure
the root of the ascending aorta at baseline with echocar-
diography in both male and female patients. Upon sus-
picion of dilation, and/or presence of left ventricular hy-
pertrophy, investigations are completed with thoracic MR
(or with computed tomography angiography in the case of
contraindications for MR). If a dilation/aneurysm is con-
firmed, monitoring of the ascending aorta is performed
every 1 to 2 years with echocardiography (root of aorta)
and 2 to 4 years with CMR. Associated risk factors for
accelerated aortic dilation, such as a bicuspid aortic valve
and/or arterial hypertension, should be detected and treat-
ed. Additionally, prophylactic treatment with beta-blockers
has to be considered [25]. In the absence of any specific
data concerning the risk of aortic dissection in Fabry dis-
ease patients, a surgical intervention should be evaluated
for ascending aortic diameters ≥55 mm.
Limitations of this study first include the small size of our
cohort. Although our data indicated that the progression of
aortic diameters in Fabry disease was not significantly re-
duced when ERT was started at a younger age (i.e., before
development of aortic dilatation), the cohort size might be
insufficient to definitely exclude an additional benefit of
early initiation of ERT on aortic diameter progression. A
second limitation is the absence of a matched control group
of untreated Fabry disease patients. Without such a con-
trol population, it is difficult to draw specific conclusions
about the efficacy (or the lack of efficacy) of ERT in reduc-
ing the aortic diameter progression associated with Fabry
disease. Such a control group would appear unethical as
ERT is now widely accepted as an effective treatment for
symptomatic Fabry patients. Considering these limitations,
our data nevertheless indicate that despite ERT, aortic re-
modelling remains significantly more pronounced in Fabry
patients than in the general population. Third, the predict-
ed normal aortic diameters computed from the data of the
MESA study are adjusted for age, gender and body surface
area, which appeared to be the major determinants of aortic
size. However, other potential minor determinants of aortic
diameter, including blood pressure, renal failure or ethnici-
ty, have not been taken into account in the computation and
may potentially affect the accuracy of the diameter predic-
tion in the control group.
In conclusion, male patients with the classic Fabry disease
have a high prevalence of ascending aorta dilation, related
to an accelerated aortic expansion rate whose pathological
process remains unclear. The progression of this aortic re-
modelling appears to be more pronounced in male Fabry
patients as compared with the progression expected in the
normal population, even if ERT is initiated before any aor-
tic dilation is present. Conversely, the aortic diameter ap-
pears to remain relatively stable in female patients treated
with ERT. Further studies are needed to better charac-
terise the pathological mechanism and the natural history
of aortic remodelling in order to better define the follow-
up and prognosis of aortic dilation in Fabry disease. In the
meantime, Fabry disease patients with aortic dilation or
aneurysm should be managed in accordance with the cur-
rent European guidelines [25].
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